Psoriasis

Apremilast Safely Treats Patients with Psoriasis, Psoriatic Arthritis in Real-World Setting

September 30, 2022

A long-term, post-authorization safety study of adverse events was performed for patients with PsO and/or PsA exposed to apremilast.

JAK Inhibitors may Serve as Additional Option to Treat Psoriasis, Psoriatic Arthritis

September 28, 2022

“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”

Bimekizumab Provides Long-Term Skin Clearance in Moderate-to-Severe Plaque Psoriasis

September 15, 2022

Bimekizumab provided maintenance of completely clear skin and health-related quality of life in most patients with moderate-to-severe plaque psoriasis over a 3-year period.

Causal Link Found Between IBD and Psoriasis, Psoriatic Arthritis

September 14, 2022

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, frequently co-occurs with the immune-mediated inflammatory condition, psoriasis.

Deucravacitinib Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

September 10, 2022

Bristol Myers Squibb announced the US FDA has approved their first-in-class, oral, selective, allosteric TYK2 inhibitor, deucravacitinib (Sotkytu), for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

FDA Approves Roflumilast Cream for Adolescents with Plaque Psoriasis

August 01, 2022

The cream's approval, based on findings from the phase 3 DERMIS trial, makes the topical PDE4 inhibitor the first of its kind approved for treating plaque psoriasis.

Long-term Data Suggests Deucravacitinib Safe, Effective for Treating Plaque Psoriasis

May 12, 2022

Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.

Jeffrey Stark, MD: Latest Bimekizumab Data for Treatment of Psoriatic Arthritis, Psoriasis

April 26, 2022

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

Deucravacitinib Effectively Treats Moderate-to-Severe Plaque Psoriasis

January 20, 2022

Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”

Jeffrey Stark, MD: Safety and Efficacy of Bimekizumab as Psoriasis Treatment

October 18, 2021

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.